Question-and-Answer Session
Operator
(Operator Instructions) Your first question comes from [Doug Subleman] - Sanford Bernstein
[Doug Subleman] - Sanford Bernstein
Can we get an update on when we might see the Prevnar 13 data in adults for the Phase three program, and is that likely to occur before the end of the year?
Justin Victoria
The Phase three program for Prevnar 13 in adults is ongoing. Frankly we do not expect to present the data at a medical conference in 2009. It will probably be in 2010 before we are in a position to be able to disclose the full data from that program. As Joe and Bernard both mentioned we’ll be filing for Prevnar 13 for adult registration in global filings in 2010.
Operator
Your next question comes from Jami Rubin – Goldman Sachs
Jami Rubin – Goldman Sachs
A follow up on Prevnar 13 for children, a couple questions, how much room do you think you have on price relative to Prevnar and are you doing studies to show benefits of revaccination of older kids of Prevnar 13, and how should we think about the commercial opportunity of Prevnar 13 in the US? I’m assuming this is just a replacement of the older formulation with the upside being the price premium but if you could elaborate on that.
Secondly, if you could talk about the opportunity overseas and the competitive dynamics with Glaxo competing pneumococcal vaccine, the vaccine.
Joe Mahady
The pricing we believe Prevnar 13 is a product that offers an improved profile over a product that’s already turned in some pretty significant performances worldwide. We’d be looking for a price premium where we can attain it and certainly that would be something we’d expect to see in the US and depending on competitive conditions worldwide something we will be pursuing in both NIP and private markets worldwide.
We do have work done to try and pursue catch up with the Prevnar 13 that would be with all the children. Again, that’s going to be dependant upon how the regulatory authorities view the registration package. The big question I think you’ve asked is how we see Prevnar stacking up in the infant and children indications worldwide given the presence of the Synflorix vaccine.
We view Prevnar 13 really as the most comprehensive protection against invasive pneumococcal disease that will be available to the worldwide markets. We think at the end of the day that’s what people have really pushed for NIPs for is for protection against serious invasive pneumococcal disease. We think Prevnar 13 will have the most comprehensive package for that.
- To read the full transcript on Seeking Alpha, click here »
